Emergent Biosolutions, Inc. (EBS) Social Stream
Emergent BioSolutions Inc (EBS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering EBS.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 44 weeks, EBS's average price target has gone down $30.34.
EBS reports an average of 58.97% for its upside potential over the past 48 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
EBS Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 35 weeks, EBS's average broker recommendation rating improved by 0.22.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- In the context of all US stocks, Emergent BioSolutions Inc's variance in analysts' estimates is lower than -412.52% of them.
- In terms of how Emergent BioSolutions Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 551.06% of that group.
- In terms of how Emergent BioSolutions Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is greater than 168.25% of that group.
- Emergent BioSolutions Inc's number of analysts covering the stock is higher than 299.88% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, DVAX, DCPH, and CYTK are the three stocks most similar to Emergent BioSolutions Inc regarding the price target and analyst recommendation information presented here.
Is EBS a Buy, Hold or Sell? See the POWR Ratings now!